Analytical Data
-
基因名
HLA-A*02:01&B2M&NY-ESO-1(SLLMWITQC) Monomer
- Application
-
别名
rHuHLA-A*0201 NY-ESO-1 complex Protein, His; MHC; MY-ESO-1; HLA-A*0201 NY-ESO-1 complex Protein
-
种属
Human
-
表达系统
HEK293
-
标签
C-10*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01892 (G25-I308, A269V)&P61769
-
表达区间
P01892 (G25-I308, A269V)&P61769 (I21-M119)&SLLMWITQC
-
氨基酸序列
SLLMWITQC&IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM&GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWVAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPI
-
分子量
55-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/NY-ESO-1 (SLLMWITQC) monomeric recombinant protein is rooted in the broader context of cancer immunotherapy and antigen presentation. NY-ESO-1 is a cancer/testis antigen frequently overexpressed in various malignancies, making it an attractive target for immunotherapeutic strategies. The HLA-A*02:01 molecule is a widely studied human leukocyte antigen (HLA) that plays a critical role in presenting peptide antigens to T cells, thereby initiating an immune response. The binding of the NY-ESO-1-derived peptide SLLMWITQC to HLA-A*02:01 is crucial for the activation of cytotoxic T lymphocytes (CTLs) that can recognize and eliminate cancer cells expressing this antigen. By producing a stable HLA-A*02:01/B2M/NY-ESO-1(SLLMWITQC) monomeric recombinant protein, researchers aim to elucidate the structural and functional dynamics of this peptide-HLA complex. This research can provide valuable insights into T cell receptor (TCR) recognition and specificity, potentially informing the development of advanced cancer vaccines and adoptive T cell therapies. The integration of insights gained from studying this monomer can advance our understanding of immune responses in cancer and enhance the design of targeted therapies that leverage the body’s immune system to fight tumors.
